{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:33:43Z","timestamp":1791516823792,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jpba.2026.117418","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:43:25Z","timestamp":1771001005000},"page":"117418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive doping research"],"prefix":"10.1016","volume":"273","author":[{"given":"Hana","family":"Alhalabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Borschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6677-5488","authenticated-orcid":false,"given":"Christelle","family":"Le Foll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1199-0743","authenticated-orcid":false,"given":"Andreas","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1993-7672","authenticated-orcid":false,"given":"Lia","family":"Bally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1535-6451","authenticated-orcid":false,"given":"Mario","family":"Thevis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jpba.2026.117418_bib1","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1586\/14789450.2014.965159","article-title":"Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions","volume":"11","author":"Thevis","year":"2014","journal-title":"Expert Rev. Proteom."},{"key":"10.1016\/j.jpba.2026.117418_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2024.171149","article-title":"Recent advances in peptide-based therapies for obesity and type 2 diabetes","volume":"173","author":"Bailey","year":"2024","journal-title":"Peptides"},{"key":"10.1016\/j.jpba.2026.117418_bib3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2165\/00007256-199418040-00004","article-title":"Effects of bodyweight reduction on sports performance","volume":"18","author":"Fogelholm","year":"1994","journal-title":"Sports Med."},{"key":"10.1016\/j.jpba.2026.117418_bib4","unstructured":"B. Buntz, Novo Nordisk achieves 74% growth surge, clinching fastest-growing pharma title, 2024\u3008https:\/\/www.drugdiscoverytrends.com\/novo-nordisk-glp1-therapies-fuel-growth-transforming-obesity-care\/\u3009(accessed 13.06.2025.2024).."},{"key":"10.1016\/j.jpba.2026.117418_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101882","article-title":"Pharmacotherapy of obesity: an update on the available medications and drugs under investigation","volume":"58","author":"Chakhtoura","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jpba.2026.117418_bib6","unstructured":"H. Mylappagari, S. Shukla, Obesity: Key Pipeline Developments and Clinical Trial Insights, 2024\u3008https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/library\/articles\/obesity-key-pipeline-developments-and-clinical-trial-insights.pdf\u3009(accessed 03.11.2025.).."},{"issue":"1","key":"10.1016\/j.jpba.2026.117418_bib7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s43441-025-00875-y","article-title":"Incretin dominance and emerging mechanisms in obesity pharmacotherapy: insights from 275 Registered Clinical Trials (2019-2024)","volume":"60","author":"Dos Santos Barbosa","year":"2026","journal-title":"Ther. Innov. Regul. Sci."},{"issue":"10520","key":"10.1016\/j.jpba.2026.117418_bib8","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/S0140-6736(25)02155-5","article-title":"Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial","volume":"406","author":"Billings","year":"2025","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.jpba.2026.117418_bib9","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2174\/1381612013397357","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control","volume":"7","author":"Weyer","year":"2001","journal-title":"Curr. Pharm. Des."},{"issue":"_3","key":"10.1016\/j.jpba.2026.117418_bib10","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.2337\/diabetes.53.suppl_3.S233","article-title":"Amylin agonists: a novel approach in the treatment of diabetes","volume":"53","author":"Schmitz","year":"2004","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.jpba.2026.117418_bib11","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1124\/jpet.121.000567","article-title":"AM833 is a novel agonist of calcitonin family G protein\u2013coupled receptors: pharmacological comparison with six selective and nonselective agonists","volume":"377","author":"Fletcher","year":"2021","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"7-8","key":"10.1016\/j.jpba.2026.117418_bib12","first-page":"1082","article-title":"Pramlintide for the treatment of diabetes mellitus","volume":"37","author":"Kleppinger","year":"2003","journal-title":"Ann. Pharm."},{"issue":"2","key":"10.1016\/j.jpba.2026.117418_bib13","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2337\/diaspect.23.2.124","article-title":"Pramlintide: clinical strategies for success","volume":"23","author":"Alrefai","year":"2010","journal-title":"Diabetes Spectr."},{"issue":"3","key":"10.1016\/j.jpba.2026.117418_bib14","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1345\/aph.1M210","article-title":"The role of pramlintide for weight loss","volume":"44","author":"Dunican","year":"2010","journal-title":"Ann. Pharmacother."},{"issue":"1","key":"10.1016\/j.jpba.2026.117418_bib15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/CRD.0000000000000513","article-title":"Cagrilintide: a long-acting amylin analog for the treatment of obesity","volume":"32","author":"D\u2019Ascanio","year":"2024","journal-title":"Cardiol. Rev."},{"key":"10.1016\/j.jpba.2026.117418_bib16","first-page":"577","article-title":"Chemical strategies for half-life extension of biopharmaceuticals: lipidation and its alternatives","author":"Bech","year":"2018","journal-title":"ACS Publ."},{"issue":"10286","key":"10.1016\/j.jpba.2026.117418_bib17","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2\u00b7 4 mg for weight management: a randomised, controlled, phase 1b trial","volume":"397","author":"Enebo","year":"2021","journal-title":"Lancet"},{"issue":"10403","key":"10.1016\/j.jpba.2026.117418_bib18","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2\u00b7 4 mg with once-weekly semaglutide 2\u00b7 4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jpba.2026.117418_bib19","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2502082","article-title":"Cagrilintide\u2013semaglutide in adults with overweight or obesity and type 2 diabetes","author":"Davies","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2026.117418_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113842","article-title":"Does receptor balance matter?\u2013Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models","volume":"156","author":"Larsen","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.jpba.2026.117418_bib21","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1124\/jpet.119.263723","article-title":"The dual amylin and calcitonin receptor agonist, KBP-066, induces an equally potent weight loss across a broad dose range while higher doses may further improve insulin action","volume":"373","author":"Sonne","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.jpba.2026.117418_bib22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13075-024-03361-2","article-title":"The dual amylin and calcitonin receptor agonist KBP-336 elicits a unique combination of weight loss, antinociception and bone protection\u2013a novel disease-modifying osteoarthritis drug","volume":"26","author":"Mohamed","year":"2024","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jpba.2026.117418_bib23","unstructured":"ClinicalTrials.gov, Phase 2 study: Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis (NCT06833749). \u3008https:\/\/clinicaltrials.gov\/study\/NCT06833749?intr=KBP-336&rank=1\u3009, 2025 (accessed 20.08.2025.2025)."},{"key":"10.1016\/j.jpba.2026.117418_bib24","unstructured":"WADA, The 2024 Monitoring Program. \u3008https:\/\/www.wada-ama.org\/sites\/default\/files\/2023-09\/2024_list_monitoring_program_en_final_22_september_2023.pdf\u3009, 2023 |."},{"key":"10.1016\/j.jpba.2026.117418_bib25","unstructured":"WADA, The 2025 Monitoring Program. \u3008https:\/\/www.wada-ama.org\/sites\/default\/files\/2024-09\/2025_list_monitoring_program_en_final_clean_11_september_2024.pdf\u3009, 2024 |."},{"key":"10.1016\/j.jpba.2026.117418_bib26","unstructured":"WADA, The 2026 Monitoring Program. \u3008https:\/\/www.wada-ama.org\/sites\/default\/files\/2024-09\/2025_list_monitoring_program_en_final_clean_11_september_2024.pdf\u3009, 2025 |."},{"issue":"5","key":"10.1016\/j.jpba.2026.117418_bib27","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1515\/cclm-2019-1009","article-title":"Identification of metabolites of peptide-derived drugs using an isotope-labeled reporter ion screening strategy","volume":"58","author":"Thomas","year":"2019","journal-title":"Clin. Chem. Lab Med"},{"issue":"1","key":"10.1016\/j.jpba.2026.117418_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/psc.2710","article-title":"In vitro models for metabolic studies of small peptide hormones in sport drug testing","volume":"21","author":"Esposito","year":"2014","journal-title":"J. Pept. Sci."},{"issue":"11-12","key":"10.1016\/j.jpba.2026.117418_bib29","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1002\/dta.2306","article-title":"Characterization of in vitro generated metabolites of selected peptides< 2 kDa prohibited in sports","volume":"9","author":"Thomas","year":"2017","journal-title":"Drug Test. Anal."},{"issue":"7-8","key":"10.1016\/j.jpba.2026.117418_bib30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/ansa.202200027","article-title":"Probing for peptidic drugs (2\u201310 kDa) in doping control blood samples","volume":"3","author":"Thomas","year":"2022","journal-title":"Anal. Sci. Adv."},{"issue":"2","key":"10.1016\/j.jpba.2026.117418_bib31","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3390\/metabo12020146","article-title":"Investigations into the In Vitro Metabolism of hGH and IGF-I Employing Stable-Isotope-Labelled Drugs and Monitoring Diagnostic Immonium Ions by High-Resolution\/High-Accuracy Mass Spectrometry","volume":"12","author":"Krombholz","year":"2022","journal-title":"Metabolites"},{"issue":"4","key":"10.1016\/j.jpba.2026.117418_bib32","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41587-023-01690-2","article-title":"Integrative analysis of multimodal mass spectrometry data in MZmine 3","volume":"41","author":"Schmid","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jpba.2026.117418_bib33","unstructured":"WADA, Minimum criteria for chromatographic-mass spectrometric confirmation of the identity of analytes for doping control purposes \u3008https:\/\/www.wada-ama.org\/sites\/default\/files\/resources\/files\/td2021idcr_final_eng_0.pdf\u3009, 2020 (accessed 02.12.2025.)."},{"issue":"10","key":"10.1016\/j.jpba.2026.117418_bib34","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s40262-013-0079-0","article-title":"Pharmacokinetics and pharmacokinetic\u2013pharmacodynamic correlations of therapeutic peptides","volume":"52","author":"Diao","year":"2013","journal-title":"Clin. Pharmacokinet."},{"issue":"12","key":"10.1016\/j.jpba.2026.117418_bib35","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.3390\/pharmaceutics13122065","article-title":"Protease-resistant peptides for targeting and intracellular delivery of therapeutics","volume":"13","author":"Lucana","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1-3","key":"10.1016\/j.jpba.2026.117418_bib36","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0014-5793(04)00300-X","article-title":"Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions","volume":"563","author":"Schilling","year":"2004","journal-title":"FEBS Lett."},{"key":"10.1016\/j.jpba.2026.117418_bib37","unstructured":"Astrazeneca, SYMLIN\u00ae (pramlintide acetate). \u3008https:\/\/medicalinformation.astrazeneca-us.com\/home\/prescribing-information\/symlin.html#S2_2\u3009 2005 (accessed 01.09.2025.2025)."},{"issue":"7","key":"10.1016\/j.jpba.2026.117418_bib38","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1177\/0091270007300949","article-title":"Pharmacokinetics of an oral drug (acetaminophen) administered at various times relative to subcutaneous injection of pramlintide in subjects with type 2 diabetes","volume":"47","author":"Kellmeyer","year":"2007","journal-title":"J. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.jpba.2026.117418_bib39","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.2337\/dc08-0029","article-title":"Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity","volume":"31","author":"Smith","year":"2008","journal-title":"Diabetes Care"},{"issue":"10317","key":"10.1016\/j.jpba.2026.117418_bib40","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial","volume":"398","author":"Lau","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jpba.2026.117418_bib41","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1021\/pr300955f","article-title":"In-source fragmentation and the sources of partially tryptic peptides in shotgun proteomics","volume":"12","author":"Kim","year":"2013","journal-title":"J. Proteome Res."},{"issue":"4","key":"10.1016\/j.jpba.2026.117418_bib42","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00259-010-1685-9","article-title":"Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient mice","volume":"38","author":"Vegt","year":"2011","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526000865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526000865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T18:07:29Z","timestamp":1777572449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708526000865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":42,"alternative-id":["S0731708526000865"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117418","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive doping research","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117418","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117418"}}